BioInvent International AB: Interim report January-June 2022


LUND, SWEDEN/ACCESSWIRE/August 25, 2022/ BioInvent International (STO:BINV)

“The second quarter of 2022 was eventful for BioInvent, delivering an agreement with US biotech company Exelixis, positive progress in our clinical pipeline and strengthened organizational leadership. All of this was followed by a successful financing in July. five clinical studies and in several cases we have reported positive data supporting their great potential.” – Martin Welschof, CEO of BioInvent.

• BI-1206 advances to Phase 1/2a study expansion stage in NHL after productive FDA Phase 1 end-of-study meeting
• BioInvent appoints Sylvie Ryckebusch as Chief Business Officer
• (R) Exelixis and BioInvent have established an exclusive option and license agreement to develop novel antibody-based immuno-oncology therapies
• Transgene and BioInvent announce positive advances for BT-001
• BioInvent and Transgene announce a collaboration and clinical trial supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
• €0.5m milestone payment received from Bayer/Hope Medicine license agreement

• (R) BioInvent successfully completed a directed equity offering of approximately SEK 300 million (approximately USD 28.3 million)
• (R) Natalie Berner of Redmile and Nanna Lüneborg of Forbion elected new members of the BioInvent Board of Directors
• BioInvent has received the initial payment of 25 MUSD from the option and license agreement with Exelixis
• First patient enrolled in the Phase 1/2a trial evaluating BI-1607 for the treatment of HER2 positive solid tumors

(R)= Regulatory event

Second quarter 2022
• Net sales of 270.9 (5.3) million SEK.
• Profit after tax of SEK 167.4 (-57.3) million.
• Earnings after tax per share before and after dilution 2.86 SEK (-0.98).
• Cash flow from operating activities -62.5 (-63.1) million SEK.

January – June 2022
• Net sales of 287.6 (11.5) million SEK.
• Profit after tax of 99.7 (-137.1) million SEK.
• Earnings after tax per share before and after dilution 1.71 SEK (-2.75).
• Cash flow from operating activities -142.3 (-112.6) million SEK.
• Cash, current and long-term investments as of June 30, 2022: 1,214.6* (1,509.7) million SEK.

* This amount does not include the initial Exelixis SEK 255.8 million (USD 25 million) fee received in July 2022, and the net capital of the directed share issue, approx. SEK 280 million, also received in July 2022.

The full interim report is available for download below and on the company’s website

For more information, please contact:
Cecilia Hofvander, Senior Director of Investor Relations
Telephone: +46 (0)46 286 85 50
E-mail: [email protected]

BioInvent International AB (publisher)
Co. Reg. Org No.: 556537-7263
Visiting address: Ideongatan 1
Postal address: 223 70 LUND
Telephone: +46 (0)46 286 85 50

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotechnology company discovering and developing first-in-class novel immunomodulatory antibodies for the treatment of cancer, with currently four drug candidates in five ongoing clinical programs in Phase 1/ 2 trials for the treatment of hematological cancer and solid tumors, respectively. The company’s validated and proprietary FIRST™ technology platform simultaneously identifies targets and the antibodies that bind to them, generating many promising new drug candidates to feed into the company’s own clinical development pipeline or for in-licensing and additional partnerships.

The Company generates revenue from research collaborations and licensing agreements with several leading pharmaceutical companies, as well as antibody production for third parties in the Company’s fully integrated manufacturing unit. More information is available at Follow on Twitter: @BioInvent.

This information is information that BioInvent International is required to make public under stock market law. The information has been submitted for publication, through the contact persons listed above, on 2022-08-25 08:00 CEST.


BioInvent Q2, 2022 EN Final

THE SOURCE: BioInvent International


Comments are closed.